Abstract: Hypoxia imaging agents can selectively accumulate in hypoxic tissues or cells. With the advance of PET imaging technique, tumor hypoxia imaging for PET has great clinical value for guiding tumor therapy, evaluating therapeutic efficacy and estimating prognosis. ¹⁸F-FMISO is the widely studied PET tumor hypoxia imaging agent containing nitroimidazole, but it still has some disadvantages. Up to now, more and more novel PET tumor hypoxia imaging agents containing nitroimidazole are under investigation. This review briefly introduced some the research progress of tumor hypoxia imaging agents containing nitroimidazole for PET.